Immunotherapy of myositis: issues, concerns and future prospects
- 2 February 2010
- journal article
- review article
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 6 (3) , 129-137
Abstract
The main inflammatory myopathies within the myositis group include polymyositis, dermatomyositis and inclusion-body myositis (IBM). Although potentially treatable, various practical issues have an impact on the response of these conditions to therapy. The most common reason for therapeutic failure is that the treatment targets the wrong disease, often owing to poor distinction of polymyositis from difficult-to-treat mimics such as sporadic IBM, necrotizing myopathies and inflammatory dystrophies. Evidence from uncontrolled studies suggests that polymyositis and dermatomyositis respond to treatment with prednisone at least to some degree. Empirically, adding an immunosuppressive drug might offer a 'steroid-sparing' effect or perhaps additional benefit. Intravenous immunoglobulin is proven effective as a second-line agent in patients with dermatomyositis and also seems to be effective for those with polymyositis, but offers only minimal and transient benefit to a small proportion of patients with IBM. Small, uncontrolled series suggest other agents such as rituximab or tacrolimus might offer some benefit in disease refractory to the aforementioned therapies, although IBM is resistant to most therapies. Novel agents are emerging as potential treatment options for all forms of myositis. This Review highlights common pitfalls in therapy, discusses emerging new therapies, and provides a practical therapeutic algorithm.Keywords
This publication has 76 references indexed in Scilit:
- Malignancy Is Associated with Dermatomyositis But Not Polymyositis in Northern New England, USAThe Journal of Rheumatology, 2009
- Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositisBrain, 2009
- B cells as therapeutic targets in autoimmune neurological disordersNature Clinical Practice Neurology, 2008
- Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscleBrain, 2008
- Daclizumab phase II trial in relapsing and remitting multiple sclerosisNeurology, 2007
- Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravisClinical Rheumatology, 2004
- Therapeutic Approaches in Patients with Inflammatory MyopathiesSeminars in Neurology, 2003
- Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapyBrain, 1997
- Current treatment of the inflammatory myopathiesCurrent Opinion in Rheumatology, 1994
- Microvascular Deposition of Complement Membrane Attack Complex in DermatomyositisNew England Journal of Medicine, 1986